B-Lymphoblastic Leukemia / Lymphoma
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DIS-B-ALL |
|---|---|
| Type | Disease |
| Aliases | B-ALLB-LBLB-Lymphoblastic Leukemia/LymphomaB-лімфобластна лейкемія/лімфомаPre-B ALL |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-NCCN-BCELL-2025 |
Informational support. All recommendations must be verified by a qualified oncologist. Engineering checks are not clinical validation or treatment approval.
| icd_o_3_morphology | 9811/3 |
|---|---|
| icd_10 | C91.0 |
| who_classification | Precursor lymphoid neoplasms — B-lymphoblastic leukaemia/lymphoma per WHO 5th ed. |
Notes
STUB — pending Clinical Co-Lead approval. MRD-driven therapy кардинально важливий — flow cytometry або PCR/NGS MRD post-induction визначає consolidation choice. Ph+ B-ALL ВИМАГАЄ initial BCR::ABL1 PCR baseline. CNS prophylaxis (IT MTX/cytarabine + HD-MTX intercalated) mandatory.
Used By
Actionability
BMA-BCR-ABL1-F317L-BALL- F317L in Ph+ B-ALL — same kinase-domain consequence as in CML: dasatinib resistance with...BMA-BCR-ABL1-P190-BALL- Ph+ B-ALL (typically p190) requires TKI-incorporating regimens. Modern trials (D-ALBA, Fo...BMA-BCR-ABL1-P210-BALL- p210 BCR-ABL1 in B-ALL (~30% of adult Ph+ ALL, much rarer in pediatric) — needs careful d...BMA-BCR-ABL1-T315I-BALL- T315I in Ph+ B-ALL — same biological consequence as in CML: pan-resistance to 1st/2nd-gen...BMA-FLT3-ITD-B-ALL- FLT3-ITD in B-ALL is rare (~1-3% adult; enriched in MLL/KMT2A- rearranged infant ALL). Gi...BMA-IDH1-R132H-B-ALL- IDH1 mutation in B-ALL is rare. Tissue-agnostic ivosidenib not approved in lymphoid; per...BMA-KMT2A-REARR-B-ALL- Revumenib (menin inhibitor) FDA-approved (Nov 2024) for relapsed/refractory KMT2A-rearran...
Algorithms
ALGO-B-ALL-1L- ALGO-B-ALL-1LALGO-B-ALL-2L- ALGO-B-ALL-2L
Disease
Indication
IND-B-ALL-1L-PH-NEG- IND-B-ALL-1L-PH-NEGIND-B-ALL-1L-PH-POS- IND-B-ALL-1L-PH-POSIND-B-ALL-2L-INOTUZUMAB- IND-B-ALL-2L-INOTUZUMABIND-B-ALL-3L-TISAGENLECLEUCEL- IND-B-ALL-3L-TISAGENLECLEUCELIND-B-ALL-BLINATUMOMAB-MRD-OR-RR- IND-B-ALL-BLINATUMOMAB-MRD-OR-RRIND-B-ALL-POST-CONSOLIDATION-POMP-MAINTENANCE- IND-B-ALL-POST-CONSOLIDATION-POMP-MAINTENANCEIND-ETV6-CARRIER-INTENSIFIED- IND-ETV6-CARRIER-INTENSIFIEDIND-ETV6-CARRIER-SURVEILLANCE- IND-ETV6-CARRIER-SURVEILLANCE
Questionnaires
QUEST-B-ALL-1L-STUB- B-Lymphoblastic Leukemia/Lymphoma — first line
Red flag
RF-B-ALL-CNS-LEUKEMIA- B-ALL with CNS-2 (CSF blasts, WBC <5/µL) or CNS-3 (CSF WBC ≥5/µL with blasts, or cranial...RF-B-ALL-EMERGENCY-TLS-LEUKOSTASIS- B-ALL with hyperleukocytosis (WBC ≥100 K/µL — Ph+ B-ALL especially), tumor lysis syndrome...RF-B-ALL-FRAILTY-AGE- Age ≥65 OR ECOG ≥3 with comorbidities — pediatric-inspired regimens (CALGB 10403, hyper-C...RF-B-ALL-HIGH-RISK-BIOLOGY- Philadelphia-positive B-ALL (BCR-ABL1+) — TKI (imatinib/dasatinib/ponatinib) + chemothera...RF-B-ALL-INFECTION-SCREENING- HBV/HCV/HIV/CMV serology + latent TB testing mandatory pre-induction; rituximab-containin...RF-B-ALL-ORGAN-DYSFUNCTION- Cardiac dysfunction (LVEF <50%) — anthracycline-based induction (hyper-CVAD A, BFM-style...RF-B-ALL-TRANSFORMATION-PROGRESSION- MRD-positive at end-of-induction (≥0.01% by flow or PCR) — switch to MRD-eradication stra...RF-BALL-CD22-POS-INO-CANDIDATE- CD22 expression on lymphoblasts in relapsed/refractory B-cell acute lymphoblastic leukemi...RF-ETV6-CONFIRMED-CARRIER- Confirmed germline pathogenic / likely-pathogenic variant in ETV6 (Thrombocytopenia 5, TH...
Sources
SRC-BLAST-GOKBUGET-2018- Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphobla...SRC-CALGB-10403-STOCK-2019- A pediatric regimen for older adolescents and young adults with acute lymphoblastic leuke...SRC-ELIANA-MAUDE-2018- Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic LeukemiaSRC-INOVATE-KANTARJIAN-2016- Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic LeukemiaSRC-PACE-CORTES-2013- A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias